“CONCLUSION: Use of depot medroxyprogesterone acetate , but not very-low-dose OCPs containing desogestrel, can lead to slightly higher fasting glucose and insulin levels.”
“RESULTS: Depot medroxyprogesterone acetate , but not OCP, users experienced slightly greater increases in glucose and insulin as compared with nonhormonal users (P<.001).”